<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00335686</url>
  </required_header>
  <id_info>
    <org_study_id>MULTINEKA</org_study_id>
    <nct_id>NCT00335686</nct_id>
  </id_info>
  <brief_title>Study on the Effect of Kaletra + Nevirapine as Maintenance Bitherapy Compared to a Triple Therapy Including Kaletra + Analogues in HIV Patients</brief_title>
  <official_title>Randomised, Prospective Multicentre Clinical Study on the Effect of the Combination of Lopinavir/Rtv + Nevirapine as Maintenance Bitherapy (Without Nucleoside Analogues) in Comparison With a Triple Therapy Including Lopinavir/Rtv + Nucleoside Analogues in HIV-Infected Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Germans Trias i Pujol Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fundacio Lluita Contra la SIDA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Germans Trias i Pujol Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to evaluate the changes in mitochondrial DNA (mDNA) by means of the
      mDNA/nuclearDNA (nDNA) ratio as a marker of mitochondrial toxicity following the interruption
      of nucleoside analogues.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      At the moment it is known that mitochondrial toxicity is the main pathogenic mechanism of
      toxicity associated with nucleoside analogues, including lipoatrophy, which at facial level
      is a stigmatising factor for patients with HIV infection.

      The primary outcome measure of the design of an &quot;NTRI-sparing&quot; bitherapy is to retard the
      onset of mitochondrial toxicity or reverse it, mainly with regard to the loss of subcutaneous
      fat or lipoatrophy.

      Lopinavir/ritonavir and nevirapine are two antiretrovirals with different mutation patterns
      and with high antiviral potency. Their combination therefore guarantees antiviral success.
      The NEKA study endorses efficacy immunologically and virologically (Negredo E. et al,
      NRTI-sparing regimen. XIV International AIDS Conference. Barcelona 2002. LB PeB9021).

      Similarly, the protective effect of nevirapine on lipid metabolism would counteract the
      negative impact attributed to lopinavir/ritonavir, reducing cardiovascular risk in these
      patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2003</start_date>
  <completion_date type="Actual">March 2006</completion_date>
  <primary_completion_date type="Actual">March 2006</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary outcome measures are changes in the mDNA/nDNA ratio at each visit with regard to the baseline visit.</measure>
    <time_frame>At 24 and 48 weeks with regard to the baseline visit</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Study of the efficacy of the therapy with Lopinavir/rtv (3 tablets every 12 h) + Nevirapine (1 tablet every 12 h) in the maintenance of viral suppression and immune recovery in patients on HAART therapy for more than 9 months</measure>
    <time_frame>At 12, 24, 36 and 48 weeks.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>and CV&lt;50 copies/mL over at last 6 months</measure>
    <time_frame>At 12, 24, 36 and 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine whether the combination with Lopinavir/rtv +Nevirapine is efficacious in avoiding progression to lipoatrophy/lipodystrophy or else the reversal thereof</measure>
    <time_frame>At 24 and 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To study whether the combination with Lopinavir/rtv +Nevirapine makes it possible to control dyslipidemia associated with the use of Lopinavir/rtv on proving the &quot;lipid-lowering&quot; action of NVP</measure>
    <time_frame>At 12, 24, 36 and 48 weeks.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To check whether the simplified combination with the standard dose of Lopinavir/rtv with NVP is sufficient to maintain suppression of viral replication. Pharmacokinetic studies (PK) would be performed to estimate this point</measure>
    <time_frame>At 12, 24, 36 and 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the tolerance and safety of the combination of Lopinavir-rtv+Nevirapine .</measure>
    <time_frame>over 48 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate treatment adherence and patient quality of life (evaluated by means of the MOS_HIV questionnaire).</measure>
    <time_frame>At 12, 24, 36 and 48 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">67</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Lopinavir-rtv (Kaletra): 3 capsules (600 mg)/12 h</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Nevirapine (Viramune): 1 comp (200mg)/12h</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lopinavir-rtv (Kaletra): 3 capsules (600 mg)/12 h</intervention_name>
    <description>Lopinavir-rtv (Kaletra): 3 capsules (600 mg)/12 h</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nevirapine (Viramune): 1 comp (200mg)/12h</intervention_name>
    <description>Nevirapine (Viramune): 1 comp (200mg)/12h</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age &gt;= 18 years.

          2. HIV-1 infected patients.

          3. Patients on HAART therapy with PIs or NNRTIs.

          4. Patients with an undetectable viral load (&lt;50/80 copies/mL) over the last 6 months (at
             least 2 determinations separated by 2 months).

          5. Hepatic tests &lt; 5 times the normal value.

          6. Subject able to follow the treatment period.

          7. Women may not be of fertile age (defined as at least one year from menopause or
             undergoing any surgical sterilisation technique), or must undertake to use a barrier
             contraceptive method during the study.

          8. Signature of the informed consent

        Exclusion Criteria:

          1. Presence of opportunistic infections and/or recent tumours (&lt; 6 months).

          2. Suspicion of resistance or documented resistance to any of the investigational drugs.

          3. Suspicion of possible bad adherence.

          4. Pregnancy or breastfeeding; refusal to follow reliable contraception over the
             treatment period.

          5. Known allergic hypersensitivity to any of the investigational drugs or any similar
             drug.

          6. Patients participating in another clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bonaventura Clotet, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lluita contra la Sida Foundation-HIV Unit</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital C. Universitario de Santiago</name>
      <address>
        <city>Santiago</city>
        <state>A Coru√±a</state>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Elche</name>
      <address>
        <city>Elche</city>
        <state>Alicante</state>
        <zip>03203</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Can Mises</name>
      <address>
        <city>Ibiza</city>
        <state>Baleares</state>
        <zip>07800</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Granollers</name>
      <address>
        <city>Granollers</city>
        <state>Barcelona</state>
        <zip>08400</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mutua de Terrassa</name>
      <address>
        <city>Terrassa</city>
        <state>Barcelona</state>
        <zip>08221</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General de Castell√≥n</name>
      <address>
        <city>Castello</city>
        <state>Castell√≥n</state>
        <zip>12004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Figueres</name>
      <address>
        <city>Figueres</city>
        <state>Girona</state>
        <zip>17600</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Palam√≥s</name>
      <address>
        <city>Palam√≥s</city>
        <state>Girona</state>
        <zip>17230</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen del Toro</name>
      <address>
        <city>Mah√≥n</city>
        <state>Menorca</state>
        <zip>07701</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Nuestra Se√±ora del Rosell</name>
      <address>
        <city>Cartagena</city>
        <state>Murcia</state>
        <zip>30071</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital C. Universitario Virgen de la Victoria</name>
      <address>
        <city>Malaga</city>
        <state>M√°laga</state>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Costa del Sol</name>
      <address>
        <city>Marbella</city>
        <state>M√°laga</state>
        <zip>29600</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Central de Asturias</name>
      <address>
        <city>Asturias</city>
        <state>Oviedo</state>
        <zip>33006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Sant Joan de Reus</name>
      <address>
        <city>Reus</city>
        <state>Tarragona</state>
        <zip>43201</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Alicante</name>
      <address>
        <city>Alicante</city>
        <zip>03010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Matar√≥</name>
      <address>
        <city>Barcelona</city>
        <zip>08304</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital C. San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Marqu√©s de Valdecilla</name>
      <address>
        <city>Santander</city>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Joan XXIII de Tarragona</name>
      <address>
        <city>Tarragona</city>
        <zip>43007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Cl√≠nico de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Arnau de Vilanova</name>
      <address>
        <city>Valencia</city>
        <zip>46015</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Xeral Cies de Vigo</name>
      <address>
        <city>Vigo</city>
        <zip>36204</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>June 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 8, 2006</study_first_submitted>
  <study_first_submitted_qc>June 9, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 12, 2006</study_first_posted>
  <last_update_submitted>February 19, 2008</last_update_submitted>
  <last_update_submitted_qc>February 19, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 29, 2008</last_update_posted>
  <responsible_party>
    <name_title>LLuita Sida Foundation</name_title>
    <organization>LLuita Sida Foundation</organization>
  </responsible_party>
  <keyword>Mitochondrial toxicity</keyword>
  <keyword>Lopinavir-rtv</keyword>
  <keyword>Nevirapine</keyword>
  <keyword>DNA mitochondrial/DNA nuclear</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lopinavir</mesh_term>
    <mesh_term>Nevirapine</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>March 19, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

